- Thread Author
- #1
USC's Keck Medicine Announces Trial of Alzheimer's "Breakthrough" Drug
Researchers at USC's Keck School of Medicine announced on December 26th the commencement of Phase III clinical trials for a novel drug,NeuroClear, targeting the root cause of Alzheimer's disease. The drug, developed from research on the neuroprotective properties of a rare California lichen, showed remarkable plaque clearance and cognitive improvement in early animal and human safety trials. The announcement brings hope to millions but also sparks ethical debates about access and cost should the trial prove successful.
Researchers at USC's Keck School of Medicine announced on December 26th the commencement of Phase III clinical trials for a novel drug,NeuroClear, targeting the root cause of Alzheimer's disease. The drug, developed from research on the neuroprotective properties of a rare California lichen, showed remarkable plaque clearance and cognitive improvement in early animal and human safety trials. The announcement brings hope to millions but also sparks ethical debates about access and cost should the trial prove successful.
